Organ transplant recipients remain vulnerable to Covid-19 even after second vaccine dose.
Organ Transplant Recipients Remain Vulnerable to Covid-19 Even After Second Vaccine Dose – Johns Hopkins Medicine Original Study: Antibody Response to 2-Dose SARS-CoV-2 mRNA Vaccine Series in Solid Organ Transplant Recipients – JAMA
The post Organ transplant recipients remain vulnerable to Covid-19 even after second vaccine dose. appeared first on Links Medicus.
Observational study in Israel: Pfizer-BioNTech is 95.3% effective against SARS-CoV-2 infection.
Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data – The Lancet Commentaries: Expert reaction to Israel nation-wide study looking at Pfizer vaccine effectiveness – Science Media Centre AND Covid-19: Two doses of Pfizer […]
The post Observational study in Israel: Pfizer-BioNTech is 95.3% effective against SARS-CoV-2 infection. appeared first on Links Medicus.
Observational study in Qatar: Pfizer–BioNTech Covid vaccine is 89.5% effective against B.1.1.7 variant and 75.0% effective against B.1.351 variant. Vaccine effectiveness against severe, critical, or fatal disease with any SARS-CoV-2 variant was very high,
Effectiveness of the BNT162b2 Covid-19 Vaccine against the B.1.1.7 and B.1.351 Variants – New England Journal of Medicine Commentary: Pfizer-BioNTech vaccine offers strong protection against key variants of concern, real-world data from Qatar shows – The Washington Post Commentary on Twitter ?GET BOTH DOSES! Great variants & #COVID19 vaccine news—Pfizer/BioNTech vaccine had great efficacy […]
The post Observational study in Qatar: Pfizer–BioNTech Covid vaccine is 89.5% effective against B.1.1.7 variant and 75.0% effective against B.1.351 variant. Vaccine effectiveness against severe, critical, or fatal disease with any SARS-CoV-2 variant was very high, at 97.4%. appeared first on Links Medicus.
RCT: Novavax vaccine is 49.4% effective against B.1.351 SARS-CoV-2 variant.
Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant – New England Journal of Medicine
The post RCT: Novavax vaccine is 49.4% effective against B.1.351 SARS-CoV-2 variant. appeared first on Links Medicus.
In shock move, US backs waiving patents on COVID vaccines. “The development from the Biden administration draws cheers from public health researchers and ire from drugmakers.”
In shock move, US backs waiving patents on COVID vaccines – Nature See also: U.S. will back proposal to waive intellectual property rights and boost Covid-19 vaccine production – STAT AND Statement from the Executive Director of UNAIDS, Winnie Byanyima on the decision by the United States of America to support the TRIPS waiver for […]
The post In shock move, US backs waiving patents on COVID vaccines. “The development from the Biden administration draws cheers from public health researchers and ire from drugmakers.” appeared first on Links Medicus.
ATS Guideline: Nucleic acid–based testing for noninfluenza viral pathogens in adults with suspected community-acquired pneumonia – Testing should be considered only in patients with severe CAP and in immunocompromised patients
Nucleic Acid–based Testing for Noninfluenza Viral Pathogens in Adults with Suspected Community-acquired Pneumonia. An Official American Thoracic Society Clinical Practice Guideline News Release: New clinical practice guideline on community acquired pneumonia – American Thoracic Society
The post ATS Guideline: Nucleic acid–based testing for noninfluenza viral pathogens in adults with suspected community-acquired pneumonia – Testing should be considered only in patients with severe CAP and in immunocompromised patients appeared first on Links Medicus.
Perspective | We may never achieve long-term global herd immunity for COVID. But if we’re all vaccinated, we’ll be safe from the worst
We may never achieve long-term global herd immunity for COVID. But if we’re all vaccinated, we’ll be safe from the worst – The Conversation See also: Reaching ‘Herd Immunity’ Is Unlikely in the U.S., Experts Now Believe – The New York Times (free registration required) AND We May Never Get to Herd Immunity – Think Global Health
The post Perspective | We may never achieve long-term global herd immunity for COVID. But if we’re all vaccinated, we’ll be safe from the worst appeared first on Links Medicus.
What’s the future of vaccines linked to rare clotting disorders? Science breaks down the latest
What’s the future of vaccines linked to rare clotting disorders? Science breaks down the latest – Science
The post What’s the future of vaccines linked to rare clotting disorders? Science breaks down the latest appeared first on Links Medicus.
[Preprint] SARS-CoV-2 antibodies remain detectable 12 months after infection and antibody magnitude is associated with age and COVID-19 severity
SARS-CoV-2 antibodies remain detectable 12 months after infection and antibody magnitude is associated with age and COVID-19 severity – medRxiv Commentary: SARS-CoV-2 antibodies are detectable up to a year after infection, finds study – News Medical Commentary on Twitter Ahhh… A year has passed since people with Covid-19 were enrolled in a longitudinal study […]
The post [Preprint] SARS-CoV-2 antibodies remain detectable 12 months after infection and antibody magnitude is associated with age and COVID-19 severity appeared first on Links Medicus.
Novel coronavirus really is seasonal, study suggests
Novel coronavirus really is seasonal, study suggests – LiveScience Original study: Climate and the spread of COVID-19 – Scientific Reports
The post Novel coronavirus really is seasonal, study suggests appeared first on Links Medicus.